Balanse

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Balanse

What is Balanse: Definition, Classification, and Purpose

Quick Facts Description
Active Ingredient Betahistine (INN)
Form Oral Tablet
Pharmacological Class Antivertiginous Agent
General Purpose Relieving symptoms of vestibular dysfunction
Origin Synthetic Compound

Balanse is a medicinal product containing the single-ingredient substance Betahistine, which is classified as an antivertiginous agent. This synthetic compound is a histamine analog that is commonly administered as an oral tablet. Unlike some older agents for balance issues, Balanse is developed for its focused action on inner ear structures, minimizing generalized sedative effects.

The drug's function is centered on modulating balance signals. Betahistine's key mechanism includes improving cochlear and vestibular blood flow and promoting the brain's ability to compensate for balance issues. The medicine is intended to assist in stabilizing the body's sense of equilibrium by targeting the circulation and neural adaptation within the vestibular system.


What Type of Medicine is Balanse (Betahistine)?

Balanse belongs to the pharmacological subclass of antivertigo preparations. The active ingredient, Betahistine, is a synthetic molecule that exhibits partial H1 receptor agonist and potent H3 receptor antagonist properties. This dual action influences histamine turnover in the central nervous system. The drug’s action is intended to increase blood flow to the inner ear and facilitate the recovery of vestibular function. This specific action is clinically recognized as a strategy to address the sensation of disequilibrium.

The overall general purpose of Balanse is to reduce the frequency and intensity of episodes where a sense of stability is compromised. A typical use scenario involves long-term management of chronic conditions causing imbalance, where the goal is to promote sustained neural adaptation. The final form of Balanse is a compressed tablet, ensuring accurate oral administration of the active substance.

Regulatory References

  1. European Medicines Agency (EMA) website
  2. Betahistine Amarox Public Assessment Report (PAR)

What side effects are possible with Balanse?

Possible Side Effects and Safety Information

The safety profile of Balanse (Betahistine) is officially documented by government regulatory agencies and classified by frequency and affected body systems. Understanding these regulatory classifications is key to defining the medicine’s risk profile.

Official Adverse Reactions and Frequency

The most frequently reported adverse reactions are generally mild, affecting the gastrointestinal and nervous systems. These reactions are classified in regulatory documents based on how often they have been observed:

Frequency Classification Examples of Adverse Reactions (SOC)
Common (ge 1/100 to <1/10) Headache, Nausea, Dyspepsia (Indigestion)
Not Known (Post-marketing) Vomiting, Gastrointestinal pain, Abdominal distension, Bloating, Hypersensitivity reactions

System-Organ-Classes and Serious Events

Adverse effects are grouped into System-Organ Classes (SOCs). For Balanse, documented SOCs include Gastrointestinal Disorders (e.g., nausea, dyspepsia) and Nervous System Disorders (headache).

Serious adverse reactions are also officially documented. Hypersensitivity reactions, classified under Immune System Disorders and Skin and Subcutaneous Tissue Disorders, include potentially severe events such as Anaphylaxis and Angioneurotic Oedema (a type of allergic swelling).

Regulatory Safety Restrictions

Official labeling defines specific conditions where the medicine should not be used (Contraindications) or where caution is required (Warnings).

  • Contraindications: The medicine is not to be used by individuals with a tumour of the adrenal gland called Phaeochromocytoma, or those with known hypersensitivity to the drug substance.
  • Population Notes: Use is officially not recommended in the pediatric population (under 18 years) due to a lack of sufficient safety data. Caution is also advised for patients with a history of peptic ulcer or bronchial asthma.

Overdose and Emergency Response

The official overdose profile for Balanse (Betahistine) is documented in regulatory sources and describes a spectrum of potential manifestations. Symptoms observed with moderate-to-high ingestions, often up to 640 mg, are generally mild to moderate and include gastrointestinal distress such as nausea, vomiting, abdominal pain, dyspepsia, and dry mouth. Central nervous system effects such as somnolence (sleepiness) and ataxia (impaired coordination) have also been reported.

More severe and life-threatening complications have been observed in cases involving very high or intentional overdose, particularly when the drug was combined with other substances. These serious outcomes include convulsions/seizures, as well as pulmonary complications and cardiac complications.

Regulatory guidance mandates that upon any suspected overdose, individuals must seek immediate medical attention and contact emergency services or a poison control center right away. Treatment involves standard supportive measures because no specific antidote is known for Betahistine. Procedures may include gastric lavage or activated charcoal administration, followed by symptomatic management.

Therapeutic Uses of Balanse

What Balanse Treats: Main Uses and Benefits

Balanse (Betahistine) is a medication generally used to provide supportive symptomatic relief in clinical situations involving inner ear dysfunction, aiming to ease the overall burden of recurrent and chronic symptoms. The medicine is commonly used for the symptomatic management of Ménière's disease.

The therapeutic application of Balanse is focused on conditions characterized by periods of heightened symptoms, such as Ménière's syndrome and other vestibular disorders. It helps manage symptom clusters that may become intense or disruptive, including recurrent vertigo (spinning sensations), associated tinnitus (ringing in the ears), and the feeling of aural fullness. This supportive relief is relevant in clinical settings where patients experience these challenging manifestations.

Balanse helps manage the frequency and intensity of severe episodic vertigo attacks. It is used to address pronounced symptoms of episodic vertigo, providing support that contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Inner Ear Symptoms

Symptom Type Therapeutic Role
Vertigo (Dizziness) Helps manage the frequency and intensity of attacks.
Aural Fullness Is relevant for easing associated ear pressure.
Nausea & Vomiting Supports the patient during difficult episodes by easing distress accompanying severe episodes.

Eligibility and Restrictions for Use

Official Eligibility Profile for Balanse

The decision regarding who can and cannot use Balanse is defined by official governmental regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Absolute Contraindications

Balanse is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance or any of its formulation components. Use may also be forbidden in patients with specific, pre-existing severe comorbidities as explicitly listed in the official labeling.

Restricted Populations and Limitations

Eligibility is limited or restricted for several populations:

  • Age-Related: Use is generally not established for pediatric patients (under 18 years of age) due to insufficient efficacy and safety data. Older adults may require special caution and a lower initial dose.
  • Organ Function: Balanse is typically not recommended for patients with severe hepatic impairment or severe renal impairment due to the risk of increased drug exposure and toxicity.
  • Reproductive Status: Use is often not recommended or prohibited during pregnancy and lactation due to documented potential risk to the fetus or infant.

Patients must adhere strictly to these documented regulatory eligibility rules before initiating treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Balanse (Betahistine) documents specific interaction patterns that may alter its efficacy or its concentration in the bloodstream. These interactions are classified into pharmacodynamic and pharmacokinetic mechanisms.


Interaction with Other Histamine Agents

Betahistine acts as a histamine analog, and its co-administration with other Antihistamines (H1 antagonists) is documented to result in pharmacodynamic antagonism. This interaction means the medicinal products may mutually counteract each other's effects, potentially reducing the expected efficacy of Balanse. Some official regulatory labeling states that Betahistine should not be used in conjunction with Antihistamines.


Interactions Affecting Drug Concentration

Certain medicinal products may alter how Balanse is processed by the body, leading to a pharmacokinetic interaction.

  • Monoamine Oxidase (MAO) Inhibitors: Medications that inhibit Monoamine Oxidase (MAO), including MAO-B selective examples such as Selegiline, are shown in vitro to inhibit the metabolism of Betahistine. This effect can lead to an increased concentration of Betahistine in the bloodstream, and caution is recommended for this combination.

  • Food Intake: Taking Balanse with food results in a slower rate of absorption and a lower maximum plasma concentration (Cmax). However, regulatory data indicates that the total amount of the drug absorbed into the body remains similar regardless of meal consumption.

Mechanism of Action

How Balanse Works

Balanse acts via molecular engagement across several biological systems, primarily focusing on receptor- or enzyme-mediated signaling, thereby modifying pathway activity. It operates by engaging mechanisms that adjust overactive or dysregulated processes, influencing systemic responses.


Alteration of Specific Receptor Signaling

This domain covers Balanse's interaction with distinct cell-surface receptors governing signal transmission. The compound alters the early molecular steps initiated by these receptors, resulting in diminished mediator activity and modifying the trajectory of pathway activity.


Enzyme-Mediated Pathway Regulation

Balanse influences core systems by targeting enzymes critical for the synthesis or catabolism of specific neurotransmitters and physiological mediators. This engagement modifies key mechanistic cascades, inducing a modification in downstream regulatory feedback loops within the targeted pathways, leading to physiological adjustments influencing the observed effect profile.

Dosage and Administration Information

How to Use Balanse: Administration Guidelines

Balanse (Betahistine) is used according to specific, standardized instructions regarding its route, dosage, and frequency.


Administration and Dosage Principles

Administration of Balanse is strictly oral using the approved tablet form. The total daily dose is typically divided into two or three separate doses to be taken throughout the day.

Usage Feature Instruction
Standard Adult Dose A total daily dose ranging from 24 mg to 48 mg is common, with the dose adjusted individually to the lowest effective level.
Maximum Daily Dose The highest recommended daily limit is 48 mg.
Timing Relative to Food Tablets are instructed to be taken with or after meals. This administration method is noted to help minimize potential gastrointestinal discomfort.
Tablet Intake The tablet must be swallowed whole with water and must not be chewed.

Course Duration and Specific Population Guidance

Treatment with Balanse is typically long-term. While some response may be observed within a couple of weeks, optimal results are often obtained after several months of continuous use. Standard practice indicates that treatment continues for a sufficient period to assess the full benefit.

Age and Impairment:

  • Older Adults (Geriatric): Based on clinical data, no specific dose adjustment is routinely required.
  • Renal/Hepatic Impairment: No specific dose adjustment appears necessary in patients with kidney or liver issues based on current experience.
  • Children and Adolescents (<18 years): Use in this population is not recommended due to insufficient data on efficacy and safety.

Handling a Missed Dose:

If a dose is forgotten, the instruction is to skip the missed dose entirely and take the next scheduled dose at the usual time; a double dose must not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Balanse (Betahistine)

Evidence for use in Ménière's Disease and Syndrome

Research on Balanse has been applied in studies examining patient-reported experiences for conditions characterized by fluctuating manifestations, such as Ménière's disease. The evidence base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that summarize and analyze the data. Researchers primarily tracked outcomes related to physical discomfort and systemic imbalance, focusing on the frequency, intensity, and duration of vertigo attacks. Studies also monitored patient-reported outcomes describing discomfort from associated symptoms, including tinnitus and aural fullness.

Findings describe patterns observed in the studies related to attack occurrence and severity. However, evidence quality varies across studies, and follow-up durations were limited in many trials. Outcomes were often based on subjective patient reports, which can introduce variability. Certainty remains low regarding the consistency of results across the entire body of evidence for the measurement of attack prevention. The findings were mixed, making it difficult to separate the observations from the natural tendency of the disease to cycle.

Understanding Long-Term Studies and Follow-Up

Research explored short-term symptom changes, with many RCTs having follow-up durations typically ranging from a few weeks to several months. Long-term effects are not fully established. Observational studies describe patterns related to the long-term observation of patient experiences, but the certainty remains low compared to well-controlled trials. There is limited information for long-term outcomes, such as the sustained measurement of recurrent episodes.

What is Still Uncertain in the Research Landscape

The research highlights what is known — and what is still uncertain. Findings were mixed in some of the larger trials, suggesting that consistent data patterns across the studies remain a key challenge. The overall certainty remains low due to several research limitations, including the difficulty in designing studies for conditions where symptoms vary and reliance on subjective data. Comparative evidence against other standard treatments is either lacking or remains uncertain.

Key Studies & References

  1. Betahistine in Ménière's Disease or Syndrome: A Systematic Review
  2. Public Assessment Report Scientific discussion Betahistine Amarox 8 mg, 16 mg and 24 mg, tablets (betahistine dihydrochloride) (NL)
  3. Clinical Practice Guideline: Ménière's Disease Executive Summary (AAO-HNSF-based consensus)

Frequently Asked Questions (FAQ)

Common questions about Balanse (FAQ)

Q: What is the main reason doctors prescribe Balanse?

According to official product information, Balanse is indicated for the treatment of Ménière's syndrome. This syndrome is a condition that involves specific symptoms such as vertigo, a ringing in the ears known as tinnitus, hearing loss, and feelings of nausea.

Q: Does Balanse have long-term side effects that people worry about?

Official literature classifies known adverse reactions by how frequently they are reported, with common side effects usually affecting the stomach and nervous system. Studies reviewed in the research overview primarily consist of short-term data. Consequently, the certainty regarding long-term outcomes and sustained effects is considered low.

Q: Are there any common foods or supplements that interact with Balanse?

Authoritative sources indicate that there is insufficient data available to determine whether complementary medicines, herbal remedies, and general supplements are safe to use with Balanse. This is because these products are not typically tested for interactions in the same way as prescription drugs.

Q: What does 'contraindicated' mean in relation to Balanse?

The term 'contraindicated' is used in official regulatory documents to signify situations or specific patient groups where the medicine should not be used. This is based on an assessment where the risk of harm is understood to outweigh any potential benefit.

Q: What is the experience of patients who have used Balanse long-term?

Current research studies have mainly explored symptom changes over the short term, typically weeks to a few months. Long-term effects are not fully established, and the data on sustained outcomes, such as the sustained measurement of recurrent episodes, remain limited.

Q: Is Balanse a controlled substance or prescription-only?

Balanse is a prescription-only medication. This means that to obtain the product, it must be provided under the order or authorization of a licensed healthcare professional.

Q: Can Balanse cause weight gain or weight loss?

Official regulatory documents, which classify observed adverse reactions, do not list weight gain or weight loss as documented side effects for Balanse.

Q: Will Balanse affect my energy levels during the day?

Some official literature reports that occasional drowsiness has been noted as an undesirable effect. However, the frequency of this effect is generally classified as rare or not known from the available post-marketing data.

Q: Can I take Balanse if I also take a common over-the-counter pain reliever?

Official regulatory texts outline specific known interactions between prescription medicines. However, these documents do not contain information regarding interactions with common over-the-counter pain relievers.

Q: Does alcohol interact dangerously with Balanse?

The official interaction section notes that there has been a case report involving an interaction with ethanol (alcohol). Despite this report, the official documents do not contain a general restriction or specific warning regarding alcohol use.

Q: Can women who are pregnant or breastfeeding use Balanse?

There are no adequate data available on the use of Balanse in pregnant or breastfeeding women. For this reason, the official literature states that Balanse should be avoided unless the potential benefits are specifically determined by a healthcare provider to outweigh the unknown risks.

Q: Is the medication Balanse addictive?

Based on the safety information reviewed by regulatory agencies, Balanse is not listed as a substance with addictive or dependence-forming properties.

Q: Can Balanse affect blood pressure or heart rate?

Due to its mechanism of action on blood vessels, Balanse may cause a small fall in blood pressure in some individuals. Rare reports from post-marketing surveillance have also noted occurrences of a pounding or rapid heartbeat.

Q: Can Balanse make you dizzy or lightheaded?

Official product information, including the post-marketing surveillance reports, notes occurrences of lightheadedness or dizziness as undesirable effects.

Q: What if I accidentally take two doses of Balanse at once?

Symptoms reported in cases of overdose include nausea, drowsiness, and abdominal pain. More serious complications were observed in cases of very large intentional overdose, especially when the drug was combined with other substances.

Q: How long after taking Balanse can I drink caffeine?

Official regulatory interaction documents, which detail known medication and substance interactions, do not contain specific information regarding the use of caffeine with Balanse.

Q: Is it safe to drive or operate machinery while taking Balanse?

While regulatory studies indicate Balanse itself generally has no or negligible effects on driving ability, the symptoms of Ménière's disease can impair the ability to drive or operate machinery. For this reason, official guidance notes that the underlying condition requires caution when driving or operating machinery.

Q: Does Balanse require any special blood tests or monitoring?

The official product literature reviewed by health authorities states that there is no known interference between the drug and standard clinical laboratory tests.

Q: How does the body typically process and eliminate Balanse?

After Balanse is absorbed, it is rapidly and almost completely metabolized in the body into a substance that is inactive. This inactive substance is then primarily eliminated from the body through the urine within 24 hours.

Q: Can Balanse affect fertility in men or women?

The official product literature states that there are no adequate data available regarding the potential effects of Balanse on fertility in men or women.

How should Balanse be stored and disposed of?

How to Store and Dispose of Balanse (Official Regulatory Information)

This section outlines the storage, handling, and disposal requirements for Balanse (Balneum Plus Cream) as specified in authoritative government regulatory documents.

Requirement Official Statement
Storage Temperature Do not store above 25°C to maintain product stability.
Shelf-Life The official shelf-life is 24 months.
Critical Handling Instruct patients not to smoke or go near naked flames. Materials such as clothing, bedding, or dressings that have been in contact with the product burn more easily and present a serious fire hazard.
Disposal Any unused medicinal product or waste material must be disposed of in accordance with local requirements.

The official storage profile mandates a specific maximum temperature to ensure the product's integrity. Critical handling instructions emphasize the serious flammability risk associated with fabric contact, which persists even after washing. Final disposal requires adherence to regional waste management rules for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Balanse found in:

A-Z Index: